SCHEMBL2289309

SCHEMBL2289309

FC(F)(F)c1ccc(-c2ccsc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 7/20 0.56
CYP2A6 P11509 3/20 0.52
CYP2E1 P05181 2/20 0.52
CYP2B6 P20813 2/20 0.52
TOP1 P11387 1/20 0.48
CYP17A1 P05093 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
KCNH2 Q12809 1/20 0.44
DRD3 P35462 1/20 0.43
CTSC P53634 2/20 0.43
MAOB P27338 1/20 0.41
LPL P06858 1/20 0.41
LIPG Q9Y5X9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2782846 0.81 CYP2A6 (0.45) CYP2A6CYP2E1CYP2B6TOP1KCNH2
SCHEMBL27989815 0.81 CYP2A6 (0.74) CYP2A6CYP2E1CYP2B6CYP17A1CYP11B1
SCHEMBL27527131 0.80 CYP2A6 (0.45) KIF11CYP2A6CYP2E1CYP2B6TOP1
SCHEMBL12548175 0.78 KIF11 (0.54) KIF11CYP2A6CYP2E1CYP2B6CYP17A1
SCHEMBL13410633 0.78 KIF11 (0.78) KIF11MAOB
SCHEMBL29914837 0.78 KIF11 (0.78) KIF11MAOB
SCHEMBL197238 0.78 KIF11 (0.78) KIF11MAOB
SCHEMBL28461267 0.77 TOP1 (0.48) KIF11CYP2A6CYP2E1CYP2B6TOP1
SCHEMBL2125063 0.75 CYP2A6 (0.72) CYP2A6CYP2E1CYP2B6CYP17A1CYP11B1
SCHEMBL27523459 0.75 CYP2A6 (0.58) CYP2A6CYP2E1CYP2B6TOP1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459506-A Iridium complex capable of preparing efficient device by using 4-pyrimidine formic acid as auxiliary ligand in solution 云南师范大学 2024-08-09 CN claimed
US-9048031-B2 Method of and printable compositions for manufacturing a multilayer carbon nanotube capacitor NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2015-06-02 US claimed
US-20140182099-A1 Method of and Printable Compositions for Manufacturing a Multilayer Carbon Nanotube Capacitor NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2014-07-03 US claimed
WO-2011103025-A1 MULTILAYER CARBON NANOTUBE CAPACITOR AND METHOD OF AN PRINTABLE COMPOSITIONS FOR MANUFACTURING A MULTILAYER CARBON NANOTUBE CAPACITOR NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2011-08-25 WO claimed
US-20110205688-A1 Multilayer Carbon Nanotube Capacitor NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2011-08-25 US claimed
US-20110204020-A1 Method of and Printable Compositions for Manufacturing a Multilayer Carbon Nanotube Capacitor NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2011-08-25 US claimed
CN-118459506-A Iridium complex capable of preparing efficient device by using 4-pyrimidine formic acid as auxiliary ligand in solution 云南师范大学 2024-08-09 CN disclosed
CN-118459506-A Iridium complex capable of preparing efficient device by using 4-pyrimidine formic acid as auxiliary ligand in solution 云南师范大学 2024-08-09 CN disclosed
US-20160086741-A1 Multilayer Carbon Nanotube Capacitor NTHDEGREE TECH WORLDWIDE INC (US) 2016-03-24 US disclosed
US-9048031-B2 Method of and printable compositions for manufacturing a multilayer carbon nanotube capacitor NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2015-06-02 US disclosed
US-20140182099-A1 Method of and Printable Compositions for Manufacturing a Multilayer Carbon Nanotube Capacitor NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2014-07-03 US disclosed
US-20140139975-A1 Multilayer Carbon Nanotube Capacitor NTHDEGREE TECHNOLOGIES WORLDWIDE INC. (US) 2014-05-22 US disclosed
EP-1668058-B1 CONJUGATED POLYMERS, THEIR PREPARATION AND USE THEREOF MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 US disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 US disclosed
EP-1940767-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2008-07-09 EP disclosed
WO-2007030567-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2007-03-15 WO disclosed
WO-2007030567-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2007-03-15 WO disclosed
EP-1668058-A1 CONJUGATED POLYMERS, THEIR PREPARATION AND USE THEREOF MERCK PATENT GmbH (DE) 2006-06-14 EP disclosed
WO-2005030828-A1 CONJUGATED POLYMERS, THEIR PREPARATION AND USE THEREOF COVION ORGANIC SEMICONDUCTORS GMBH (DE) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249137-A1 PPAR active compounds PPARG, PPARA, PPARD KIF11 4491/4885CYP2A6 887/4885CYP2E1 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.